isatuximab + bortezomib + cyclophosphamide + dexamethasone

This is a **four-drug combination regimen** consisting of isatuximab, bortezomib, cyclophosphamide, and dexamethasone, used in the treatment of multiple myeloma. **Isatuximab** is a monoclonal antibody targeting CD38, resulting in anti-tumor immune-mediated cytotoxicity and apoptosis. **Bortezomib** is a proteasome inhibitor, blocking protein degradation and leading to cell cycle arrest and apoptosis of malignant plasma cells. **Cyclophosphamide** is an alkylating agent that crosslinks DNA, disrupting tumor cell proliferation. **Dexamethasone** is a synthetic glucocorticoid with lympholytic, anti-inflammatory, and pro-apoptotic activity. This quadruplet regimen has been investigated primarily in patients with **newly diagnosed multiple myeloma** (NDMM) ineligible for autologous stem cell transplantation. The exact development status for this specific combination (with cyclophosphamide) is **PHASE1** for NDMM, with ongoing studies evaluating its efficacy and safety versus other regimens, but it is not currently a standard regulatory-approved combination.

Brand names

SarclisaVelcadeCytoxanDecadron

Other names

isatuximab + bortezomib + cyclophosphamide + dexamethasone